Phaseline

Companies › Marzieh Ebrahimi

Marzieh Ebrahimi: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Active NK cell injection
Natural killer cell-based immunotherapy
–Phase 2Glioma Glioblastoma MultiformeNov 2027
Allogenic NK cells
Natural Killer cells extracted from healthy donor, processed and infused to enhance anti-t
–Phase 1Neuroblastoma, Recurrent, RefractoryNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06674265Allogenic NK cellsPhase 1Neuroblastoma, Recurrent, RefractoryOncologyNov 2026
NCT06687681Active NK cell injectionPhase 2Glioma Glioblastoma MultiformeOncologyNov 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Hrain Biotechnology Beijing Yongtai Ruike Biotechnology Company Hebei Senlang Biotechnology Hangzhou Converd Abscint NV/SA

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.